VSIR and systemic lupus erythematosus: Chen and colleagues recently reported reductions in cutaneous disease, autoantibodies, inflammatory cytokines, chemokines, and expansion of immune cells using anti–VISTA agonist antibody in a mouse model of lupus (17).